O

    Oragenics Inc (OGEN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.50
    -0.02 (-4.62%)

    Market Cap: $2.27M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(15/24)
    Avg Surprise
    -16.27%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.57N/AN/ABeat+84.4%
    Mar 26
    		$-0.51N/AN/ABeat-91.4%
    Sep 25
    		$-1.96$0.00N/AMiss-419.5%
    Jun 25
    		$-3.10$0.00N/AMiss-509.0%
    Mar 25
    		$-3.65N/AN/ABeat-420.7%
    Dec 24
    		$-0.27N/AN/ABeat+93.6%
    Sep 24
    		$-0.38N/AN/ABeat+55.8%
    Jun 24
    		$-0.51N/AN/ABeat+66.2%
    Mar 24
    		$-0.70N/AN/ABeat+98.3%
    Dec 23
    		$-4.14$3.00-237.93%Miss-272.7%
    Sep 23
    		$-0.85$0.00N/ABeat+98.4%
    Jun 23
    		$-1.51$-3.00+49.78%Beat+97.2%
    Mar 23
    		$-42.30N/A+53.01%Beat+53.0%
    Dec 22
    		$-1.11N/A+53.75%Beat+7.5%
    Sep 22
    		$-54.01$-90.01+40.00%Beat+25.0%
    Jun 22
    		$-54.01$-72.01+25.00%Beat+0.0%
    Mar 22
    		$-90.01$-36.00-150.03%Miss+0.0%
    Dec 21
    		$-1.20$-2.40+50.00%Beat+60.0%
    Sep 21
    		$-72.01$-72.01+0.00%Beat+50.0%
    Jun 21
    		$-54.01$-72.01+25.00%Beat+87.5%
    Mar 21
    		$-90.01$-72.01-25.00%Miss+54.5%
    Dec 20
    		$-3.00$-3.60+16.67%Beat+37.5%
    Sep 20
    		$-144.01$-126.01-14.28%Miss+0.0%
    Jun 20
    		$-432.04$-162.02-166.66%Miss-140.0%
    Mar 20
    		$-198.02$-144.01-37.50%Miss+0.0%
    Dec 19
    		$-4.80$-5.80+17.24%Beat+11.1%
    Sep 19
    		$-144.01$-189.02+23.81%Beat+77.1%
    Jun 19
    		$-180.02$-126.01-42.86%Miss+73.7%
    Mar 19
    		$-198.02$-153.02-29.41%Miss-47047.6%
    Dec 18
    		$-5.40$-6.00+10.00%Beat-1700.0%
    Sep 18
    		$-630.06$-378.04-66.66%Miss-149914.3%
    Jun 18
    		$-684.07$-810.08+15.56%Beat-341935.0%
    Mar 18
    		$-0.42$-0.42+0.00%Beat-5.0%
    Dec 17
    		$-0.30N/AN/ABeat+40.0%
    Sep 17
    		$-0.42N/AN/ABeat+99.9%
    Jun 17
    		$-0.20N/AN/ABeat-
    Mar 17
    		$-0.40$0.00N/ABeat-
    Dec 16
    		$-0.50$0.00N/ABeat-
    Sep 16
    		$-720.07$-720.07+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.08EV/EBITDA0.21x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-1307.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-563.32x
    Current Ratio3.01xQuick Ratio3.01x
    Trading Statistics
    Beta1.24Avg Volume37.16K
    52-Week High$1.4552-Week Low$0.48

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.53
    SMA 20$0.53
    SMA 50$0.55
    SMA 200$0.70
    EMA 10$0.52
    EMA 20$0.53
    EMA 50$0.55
    EMA 200$1.00

    MACD

    Line: -0.01Signal: -0.01Hist: -0.00

    ADX

    ADX: 15.1+DI: 13.0-DI: 24.1

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down12.0
    PSAR$0.57

    Bollinger Bands

    Upper Band$0.56
    Lower Band$0.51
    %B Position945%(Upper)
    Band Width-0.18

    RSI (14-Day)

    Neutral
    36.6

    Momentum Oscillators

    Stoch %K27.7
    Stoch %D32.7
    Williams %R-87.6
    ROC (10d)-6.5%
    Momentum-0.04
    CCI (20d)-236.3
    MFI (14d)41.0

    Volatility Measures

    ATR (14d)$0.03(5.3%)
    StdDev (20d)0.01
    Hist Vol32.2%(Moderate)

    Volume Flow

    VWAP$0.51
    OBV236.6M
    AD Line34.4B
    CMF (20d)-0.307

    Volume Metrics

    Avg Vol (20d)36.9K
    Vol Ratio2.7x(High)
    VWMA (20d)$0.53

    Pivot Points

    R3$0.54
    R2$0.54
    R1$0.53
    Pivot Point$0.53
    S1$0.52
    S2$0.52
    S3$0.51

    Advanced Oscillators

    TSI-11.01
    Ultimate Osc41.2
    KST-21.76

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$3.14M$0$0$0$-37,653$7,466
    Cost of Revenue$0$0N/A$0$0$0$1.57M$0$0$0$11.04M$0
    Gross Profit$0$0N/A$0$0$0$1.57M$0$0$0$-11,041,981$7,466
    Operating Expenses$2.59M$2.26M$2.50M$3.12M$1.71M$2.03M$3.36M$2.44M$2.31M$2.46M$12.80M$2.10M
    R&D$1.18M$645,470$670,543$930,894$449,679$341,542$1.67M$879,041$906,779$663,414$11.04M$769,350
    SG&A$1.42M$1.61M$1.83M$2.19M$1.26M$1.68M$1.69M$1.56M$1.40M$1.80M$1.75M$1.33M
    Operating Income$-2,592,528$-2,255,927$-2,498,301$-3,123,773$-1,714,202$-2,026,227$-3,355,432$-2,437,280$-2,306,000$-2,460,103$-12,796,324$-2,094,446
    Interest Income$30,026$40,876$87,091$68,142$16,793$10,203$10,791$9,466$6,405$19,235$38,626$50,613
    Interest Expense$414$3,727$7,454$7,039$572,310$199,127$10,969$9,971$1,803$7,085$0$14,170
    Income Before Tax$-2,575,084$-2,223,868$-2,423,780$-3,066,589$-2,272,035$-2,216,993$-3,349,125$-2,462,870$-2,305,090$-2,450,833$-12,747,429$-2,012,885
    Income Tax Expense$-46,377$-22,625$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,528,707$-2,201,243$-2,286,870$-3,066,589$-2,272,035$-2,216,993$-3,349,125$-2,462,870$-2,305,090$-2,450,833$-12,747,429$-2,012,885
    EBITDA$-2,604,696$-2,261,017$-2,503,417$-3,127,692$-1,137,940$-1,835,210$-3,348,947$-2,462,365$-2,309,692$-2,462,983$-12,773,824$-2,044,543
    EBIT$-2,604,696$-2,261,017$-2,503,417$-3,127,692$-1,716,518$-2,028,069$-3,348,947$-2,462,365$-2,309,692$-2,462,983$-12,773,824$-2,049,328
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OGEN

    News

    OGEN PE Ratio & Valuation, Is OGEN Overvalued

    Oragenics Inc (OGEN) is currently in the "Fair zone" according to its forward P/S ratio of 0.00, compared to its five-year average of -0.91. The company's current Price-to-Book (P/B) ratio is 0.66, which is higher than its 3-year average but lower than its 5-year average. OGEN's Forward Free Cash Flow (FCF) yield is -418.94%, significantly lower than its historical averages.

    Intellectia AI•8/24/26•
    Neutral

    Oragenics: Q2 Earnings Snapshot

    This article provides a Q2 earnings snapshot for Oragenics. Due to the limited content provided, no further details can be extracted.

    10TV•8/13/26•
    Neutral

    Oragenics (OGEN) flags going concern risk with $4.7M loss and $3.9M cash

    Oragenics (OGEN) reported a net loss of $4.7 million and had $3.9 million in cash as of June 30, 2026, leading to a "going concern" warning from its auditor and management due to recurring losses and an accumulated deficit of $231.4 million. The company expects its current capital to fund operations only through December 31, 2026, necessitating additional financing. Oragenics is a development-stage biopharmaceutical company focused on ONP-002 for concussion, which is currently in Phase IIa trials in Australia.

    Stock Titan•8/13/26•
    Bearish

    Oragenics: Q2 Earnings Snapshot

    Oragenics Inc. (OGEN) reported a loss of $2.5 million, or 57 cents per share, in its second quarter. The financial results were released on Thursday by the Lakewood Ranch, Florida-based company. This earnings snapshot was generated by Automated Insights using data from Zacks Investment Research.

    theheraldreview.com•8/13/26•
    Bearish

    OGEN|Oragenics Inc|Price:0.530|Chg%:+0.030

    This article provides a comprehensive stock analysis of Oragenics Inc (OGEN), highlighting its strong fundamentals and high growth potential despite recent weak stock market performance. The company's valuation is considered fair within the Biotechnology & Medical Research industry, and it benefits from very high institutional ownership and a favorable analyst rating. Oragenics Inc is a development-stage company focused on nasal delivery pharmaceutical medications for neurology and infectious diseases.

    TradingKey•7/31/26•
    Neutral

    Frequently Asked Questions About OGEN

    Does OGEN pay dividends?
    Oragenics Inc (OGEN) does not currently pay a regular dividend.
    What is OGEN's market cap?
    Oragenics Inc (OGEN) has a market capitalization of $2.27M with a current stock price of $0.50.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In